Techno-economic analysis (TEA) for bioprocesses

01Overview and value chain

Markers: [EC: Bioeconomy Strategy | OECD: Bioeconomy policy & governance | Regulator: FDA (USA), EMA (EU)]

Techno-Economic Analysis (TEA) for bioprocesses bridges the critical gap between bench-scale biological success and commercial-scale financial viability. In the high-risk biopharmaceutical and synthetic biology sectors, scaling up a fermentation or purification process requires massive capital expenditure, often exceeding $100 million for a commercial facility. TEA utilizes sophisticated mass-and-energy balance software to create a digital twin of the proposed biomanufacturing facility. By simulating hundreds of variables—from bioreactor titers to downstream resin binding capacities and raw material costs—TEA accurately predicts the Cost of Goods Sold (COGS) per gram of product. This rigorous mathematical forecasting enables executives and investors to identify critical process bottlenecks, optimize facility sizing, and ultimately decide whether a novel biologic or biomaterial is economically feasible to commercialize.

The key directions of techno-economic analysis are:

1. Cost of Goods Sold (COGS) Modeling (Financial modeling): Granularly calculating the contribution of raw materials, labor, utilities, and facility depreciation to the final per-gram cost of the biological product.
2. Process Bottleneck Identification (Process simulation): Utilizing software like SuperPro Designer to map the time and mass dynamics of a process, identifying exactly which equipment (e.g., a slow chromatography step) limits overall facility throughput.
3. Facility Sizing and Scale-Up Strategy (Capacity planning): Determining the optimal number and volume of bioreactors (e.g., 6 x 2000 L single-use vs. 2 x 10000 L stainless steel) required to meet projected market demand efficiently.
4. Lifecycle Assessment (LCA) Integration (Sustainability modeling): Combining traditional financial TEA with environmental impact metrics to quantify a bioprocess’s carbon footprint, water usage, and energy intensity.

Sectoral value chain

[Bench-Scale Data Aggregation] ──> [In-Silico Process Modeling] ──> [Mass & Energy Balancing] ──> [Financial & Risk Simulation]
                                  │
                          (Alternative Scenarios)
                                  │
                                  ▼
[Capital Deployment Decision] <─── [COGS & Throughput Output] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Process simulation software: Specialized platforms (like SuperPro Designer or Aspen Plus) that contain vast databases of standard biomanufacturing equipment and their operating physics.
• Monte Carlo risk analysis: Statistical modeling integrated into TEA to determine the probability of financial success given the inherent uncertainties in biological scale-up.
• Parametric cost estimation: Leveraging proprietary historical databases of biopharma construction costs to generate accurate CAPEX estimates without requiring highly detailed architectural blueprints.

02US

The United States dominates the strategic bioprocessing consulting market, fueled by an immense pipeline of venture-backed synthetic biology startups and cell and gene therapy (CGT) developers requiring rigorous financial validation.

Synbio scaling, CGT cost constraints, venture due diligence

• Venture capital validation: Top-tier venture capital firms heavily utilize specialized consultancies (like BDO’s Bioprocess Technology Group) to conduct independent TEAs before leading $50M+ Series B scaling rounds.
• Software leadership: The US is home to Intelligen, the developer of SuperPro Designer, which has become the undisputed global software standard for bioprocess modeling and TEA.
• CGT commercialization: With autologous cell therapies facing unsustainable COGS, US-based engineering firms (like CRB and IPS) are pioneering TEA models that simulate the financial impact of decentralized, “hospital-adjacent” manufacturing networks.

03CN

China’s approach to TEA is heavily focused on rapid facility deployment, import substitution, and optimizing the massive scale required for global biosimilar and active pharmaceutical ingredient (API) dominance.

Mega-scale optimization, CAPEX reduction, domestic engineering

• Facility engineering integration: Chinese firms, including local subsidiaries of Pharmadule Morimatsu, tightly integrate TEA with rapid modular facility engineering to compress the time from financial modeling to operational plant.
• CAPEX arbitrage: Chinese TEA models often demonstrate significantly lower initial capital expenditures by substituting imported European stainless-steel vessels with rapidly improving domestic bioprocessing equipment.
• CDMO scale-out: As Chinese CDMOs aggressively scale out single-use capacities, they utilize continuous TEA to dynamically optimize the balance between imported single-use consumables (OPEX) and domestic stainless-steel infrastructure (CAPEX).

04EU

The European Union’s TEA landscape is uniquely characterized by the deep integration of environmental sustainability metrics (Lifecycle Assessment) into traditional financial modeling.

Environmental LCA, continuous bioprocessing, collaborative modeling

• Dual TEA/LCA modeling: Driven by stringent EU Green Deal mandates, European biopharma engineering firms (like NNE) mandate that financial TEA runs parallel with carbon footprint and water usage modeling.
• Continuous manufacturing: European consortia and modeling groups (such as BioPhorum) are actively using TEA to prove the long-term commercial viability of shifting from traditional batch processing to fully continuous, intensified biomanufacturing.
• Heritage engineering: Europe remains the global center of excellence for massive, complex stainless-steel facility engineering, relying on decades of proprietary historical cost data to feed highly accurate TEA models.

05Leading companies and research institutes

06Tech stack and innovations

Techno-economic analysis relies on sophisticated digital tools that translate biological behavior into precise thermodynamic, kinetic, and financial equations.

1. Bioprocess Simulation Software (SuperPro Designer):
   • Object-oriented software where users drag-and-drop unit operations (e.g., bioreactors, centrifuges, chromatography columns) onto a digital flowsheet.
   • The software automatically solves hundreds of simultaneous differential equations to track the mass of every chemical component, energy use, and cycle time throughout the virtual plant.
2. Throughput and Debottlenecking Algorithms:
   • Gantt chart-style schedulers integrated into the simulation that map the precise occupancy time of every piece of equipment.
   • Automatically highlights “clashing” operations where multiple batches compete for the same downstream purification skid, allowing engineers to size buffer tanks optimally.
3. Integrated Lifecycle Assessment (LCA) Modules:
   • Emerging add-ons that map the output of the mass-and-energy balance directly to environmental impact databases (e.g., Ecoinvent).
   • Instantly translates electricity and solvent consumption into Global Warming Potential (GWP) and cumulative energy demand metrics alongside the financial COGS.

07Value chains and production pipelines

Industrial pipeline of Biomanufacturing TEA Development (ISO 9001)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Process assumption def.│ ───> │ 2. Flowsheet construction │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Cost database linkage  │ <─── │ 3. Mass/Energy simulation │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Sensitivity analysis   │ ───> │ 6. Final executive report │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Process assumption definition

Consultants collaborate with the client’s R&D scientists to define the baseline assumptions: target annual production volume, expected bioreactor titers (g/L), downstream step yields, and overall batch duration.

Stage 2: Flowsheet construction

The consultant builds the digital twin in a simulation environment, selecting the appropriate scale of equipment (e.g., a 2000 L single-use bioreactor followed by a continuous centrifuge) and mapping the connections.

Stage 3: Mass/Energy simulation

The software executes the simulation, rigorously balancing every input and output. It determines exactly how many liters of Water for Injection (WFI), kilograms of media, and kilowatt-hours are required per batch.

Stage 4: Cost database linkage

The physical resource requirements are mapped against proprietary databases of current market prices for raw materials, specialized labor rates, and capital equipment purchasing costs.

Stage 5: Sensitivity analysis

Engineers run Monte Carlo simulations or tornado chart analyses, tweaking highly uncertain variables (like a +/- 20% swing in bioreactor titer or protein A resin lifespan) to see how volatile the final COGS is under different scenarios.

Stage 6: Final executive report

The compiled data is translated into an actionable executive strategy document, providing a definitive Go/No-Go financial recommendation, a breakdown of COGS, and a roadmap for facility scale-up.